Request an Appointment



Contact us with Questions

Expand Content

Gary Hoffman, MD


Gary Hoffman, MD
Department: Rheumatologic and Immunologic Disease
Location: Cleveland Clinic Main Campus
Mail Code A50
9500 Euclid Avenue
Cleveland, OH 44195
Adults Only

Biographical Sketch

Gary S. Hoffman, MD, MS, received his medical degree from the Medical College of Virginia and pursued advanced training in Medicine and Rheumatology at Dartmouth Medical School. He is the Harold C. Schott Chair for Rheumatic and Immunologic Diseases, Founder of the Cleveland Clinic Center for Vasculitis Care and Research, Founder and past Chairman of the International Network for the Study of the Systemic Vasculitides (INSSYS), Chairman of the Department of Rheumatic and Immunologic Diseases at Cleveland Clinic and Professor of Medicine at Lerner College of Medicine.

Prior to joining Cleveland Clinic, he was the Head of Vasculitis and Related Diseases at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). Dr. Hoffman has led investigations of new therapies for the treatment of the systemic vasculitides. His work includes the coordination of INSSYS-based multi-center studies of new treatments and diagnostic tools to assess vasculitis disease activity. His laboratory is studying factors that may be involved in determining organ vulnerability and selective targeting in vasculitis.

Among the numerous awards he has received for contributions to vasculitis research are the NIH Director's Award, the NIAID Director's Award, the Wegener's Foundation Award for Excellence in Clinical Research, the William Ischmael, Pemberton Awards and the Maria and Sam Miller Clinical Research Award. He has been repeatedly listed among the “Best Doctors in America” and has also received awards for excellence in teaching medicine.

Dr. Hoffman is on the Editorial Boards of numerous rheumatology journals is the Editor of Inflammatory Diseases of Blood Vessels. Dr. Hoffman is a past member of the Board of Directors of the American College of Rheumatology, serves on The FDA Advisory Board and Boards of numerous lay organizations whose goals are to educate patients and support research in vasculitis.

Professional Highlights

  • Former Head of Vasculitis and Related Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
  • Led investigations of new therapies for the treatment of the systemic vasculitides

Education & Fellowships

Fellowship - Dartmouth Medical School
Hanover, NH USA
Residency - Dartmouth Medical School
Internal Medicine
Hanover, NH USA
Internship - Riverside Regional Medical Center
Medical Internship
Newport News, VA USA
Medical School - Virginia Commonwealth University Medical College
Richmond, VA USA
Graduate - Howard University
Washington, DC USA
Undergraduate - State University of New York at Binghamton
Binghamton, NY USA


  • Internal Medicine
  • Internal Medicine- Rheumatology

Specialty Interests


Awards & Honors

  • Golden Apple Award for teaching excellence, 1985
  • Awards for Teaching Excellence, 1995, 1998
  • National Institutes of Health, NIAID Director's Award, 1990, 1992
  • NIH Director's Award, 1992
  • Chairman and Founder, International Network for the Study of Systemic Vasculitis, 1991-2001 
  • Honorary Member of the Chilean Society of Rheumatology, 1995
  • “Best Doctors in America: General Rheumatology,” 1996-2007
  • Castle Connolly’s “America’s Top Doctors,” 2001-2007
  • The Twenty-Second Annual William K. Ishmael Award and Lectureship in Rheumatology (1996), University of Oklahoma
  • Mexican Society of Rheumatology, Annual Visiting Professor, 1998
  • National Institutes of Health, National Institute of Allergy and Infectious Diseases Advisory Panel for Vasculitis Research, 1998
  • National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, long range planning panel, 1999
  • Senior Faculty Host Coordinator for the ACR/EULAR International  Exchange Program, 2000- 2001
  • Board of Directors, American College of Rheumatology, 2000-2003
  • Tisdale Memorial Lecture, University of Vermont, 2000
  • Awarded Harold C. Schott Chair in Rheumatic and Immunologic Diseases, 2000
  • JFL Woodbury Lecture, Dalhousie University, 2001
  • Sommer Memorial Lecture Series, Portland 2001
  • Keynote and Co-Chair, Vasculitis.  Japanese Society of Rheumatology, 2001
  • Program Director/Host, International Vasculitis and ANCA Workshop. 2002
  • The Simon Dworkin Visiting Professor, McGill U. Medical Center. June 2002
  • The Inaugural Gene Hunder Lecture. 2nd International Conference on GCA/PMR, Mayo Clinic, August, 2002
  • 54th Annual Pemberton Lecture and Award: Pathogenesis of Large Vessel Vasculitis – What makes a vessel a target? Oct., 2004
    2005 Israeli Society of Rheumatology, Keynote Presentation: The use of biologic therapies in systemic vasculitis
  • 2006 keynote speaker: Lund Vasculitis Symposium, Sweden
  • Cleveland Clinic Miller Award for Scientific Achievement in Clinical  Research, 2007

Innovations & Patents

Patent: Cid MC, Grant DS, Hoffman GS, Kleinman HK: For “Method of stimulating angiogenesis by using haptoglobin,” U.S. Patent Serial No. 07/939, 142, accepted 1993. Issued #5,318,957; June 7, 1994


  • Fellow, American College of Physicians
  • Fellow, American College of Rheumatology

Treatment & Services

Specialty in Diseases and Conditions

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 12/10/2014, Dr. Hoffman has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Hoffman receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Celltrion, Inc.
  • Roche (Hoffman-La Roche, Ltd.)
  • Sanofi S.A.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English